Campbell & Co Investment Adviser’s Arcutis Biotherapeutics ARQT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-31,544	Closed	-$743K	–	1032
2026 Q1	$743K	Buy	+31,544	New	+$805K	0.04%	610
2025 Q4	–	Sell	-39,879	Closed	-$752K	–	1123
2025 Q3	$752K	Buy	39,879 +23,730	+147%	+$374K	0.06%	543
2025 Q2	$226K	Sell	16,149 -59,050	-79%	-$828K	0.01%	1031
2025 Q1	$1.18M	Sell	75,199 -520	-0.7%	-$7.33K	0.09%	361
2024 Q4	$1.05M	Buy	75,719 +171	+0.2%	+$1.87K	0.08%	370
2024 Q3	$703K	Buy	75,548 +12,455	+20%	+$123K	0.05%	578
2024 Q2	$587K	Buy	+63,093	New	+$571K	0.05%	594

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Campbell & Co Investment Adviser's ARQT Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 31,544 shares — an estimated $743K sold.

Campbell & Co Investment Adviser first reported a position in ARQT in Q2 2024 and held it in 7 quarters. The position peaked at $1.18M in Q1 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Campbell & Co Investment Adviser reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 31,544 Arcutis Biotherapeutics shares in Q2 2026, an estimated $743K.
Campbell & Co Investment Adviser first reported a position in Arcutis Biotherapeutics in Q2 2024 and held it in 7 quarters.
Campbell & Co Investment Adviser's Arcutis Biotherapeutics position peaked at $1.18M in Q1 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.